https://www.taplowgroup.comInsight
https://www.taplowgroup.comTaplow
https://www.taplowgroup.comKnowledge
  • News
  • Cases
  • Downloads
01.11.2016

Taplow Global Ranking

Prestigious recruitment and leadership media firm, Hunt Scanlon will announce there global top 25 search firms in June 2016.

01.11.2016

Taplow Attends Technology Fair in Copenhagen, Denmark

Taplow Denmark and Germany recently attended a Robotics Technology Fair in Copenhagen, Denmark. This joint initiative was developed to enable both...
01.11.2016

New Taplow Partners

Taplow Norway are delighted to introduce Lars Hoel, he joins to widen their ability to service the Retail and Luxury goods sectors, he joins...
First19202122232425262728

 CEO FOR A SPORTS:

Situation: A Finnish, mainly nationally operating sports company needed new CEO as the old one was about to retire. As sports business is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contac Timo Toivanen, Finland

 

 

 CEO FOR LOGISTICS:

Situation: One of the largest globally operating Logistics companies was in a need of new CIO for Finland. As Logistics and Value Chain is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contac Timo Toivanen, Finland

White Papers
  • India – The new R&D hub for Automotive

    Taplow India have conducted an in-depth review of the Automotive sector in India, For further information contact Sangeeta Sabharwal, India

    Click Here
  • Maysam Rizvi reviews the Banking Tech Revolution.

    Capital is more expensive, costs are higher and prices have gone down… the technology revolution has become a necessity.

    Click Here
  • EVOLVING BUSINESS UNITS Market Access thus becoming “transversal”

    The pharmaceutical market, in regards to the price component covered by the NHS, has been, until today, characterised by the presence of drugs of high therapeutic value, such as cancer-drugs, rheumatologic drugs, anti-infection drugs and drugs for the treatment of chronic illnesses, the vast majority of which have either seen their patent expire recently or will see it expire in the next two years.

    Click Here
  • BUSINESS CYCLES

    Present Human Capital Opportunities and Challenges:

    Click Here